Compare NYC & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYC | KTTA |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 23.2M |
| IPO Year | 2014 | N/A |
| Metric | NYC | KTTA |
|---|---|---|
| Price | $7.77 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 23.9K | ★ 417.9K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $0.28 |
| 52 Week High | $16.30 | $2.06 |
| Indicator | NYC | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 23.73 |
| Support Level | N/A | $0.28 |
| Resistance Level | $8.63 | $0.76 |
| Average True Range (ATR) | 0.73 | 0.05 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 15.21 | 3.96 |
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.